Loading stock data…
Mineralys Therapeutics (MLYS)
$26.88+0.20 (+0.75%)
Market ClosedLast close Jun 29
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Mineralys Therapeutics, Inc. in the Healthcare sector is trading at $26.88 with a market capitalization of $2.1B. Wall Street consensus targets $49.00 (8 analysts), implying a +82.3% move over the next 12 months. The stock is currently 44% below its 52-week high of $47.65, remaining 18.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 82 is overbought against a weak tape. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +82.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 82 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$45.34M↓ | -$38.28M↑ | -$41.13M↑ | -$46.75M↓ | -$44.45M |
| Net Income | -$39.34M↓ | -$32.23M↑ | -$36.93M↑ | -$43.27M↓ | -$42.21M |
Peer Comparison
JNJUNHPFE
Fundamentals
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.08B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-23.78%
Volume
Today's trading volume
1.57M
Recent News
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
This clinical-stage biotech focused on hypertension therapies reported a notable insider sale amid strong one-year stock performance.
Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the best young stocks to invest in according to hedge funds. On June 3, Mineralys Therapeutics announced the pricing of an underwritten public offering of ~5.66 million shares of its common stock at $26.50 per share. The company expects to generate ~$150 million in gross proceeds from the […]
Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 10 best AI driven biotech stocks to invest in. On June 3, Mineralys Therapeutics (NASDAQ:MLYS) shared a major update regarding its blood pressure drug, lorundrostat. The company is repurchasing its potential royalty payments from Tanabe Pharma Corporation. Mineralys is paying $200 million upfront and up to $100 […]
Mineralys Deepens Lorundrostat Bet With Royalty Buyout And New Data
Mineralys Therapeutics (NasdaqGS:MLYS) has repurchased future lorundrostat royalties from Tanabe Pharma, supported by an equity raise and a US$500m debt facility. The company has reported positive Phase 3 data for lorundrostat in both CKD and non CKD patients, presented at a major cardiovascular conference. Lorundrostat is currently under active FDA review for a New Drug Application, adding a regulatory milestone to the recent financial moves. Mineralys Therapeutics focuses on cardio renal...
Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 30, Mineralys Therapeutics Inc. (NASDAQ:MLYS) provided compelling data for the clinical efficacy of lorundrostat during the 35th European Meeting on Hypertension and Cardiovascular Protection. This clinical update comes after the company’s strategic focus on assisting […]